Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "IND"

5575 News Found

Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
Drug Approval | April 14, 2024

Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations

This facility manufactures APIs & formulations of oncology and non-oncology products.


Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData
News | April 12, 2024

Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData

A significant proportion of healthcare professionals still tend to favor branded drugs


Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India
News | April 07, 2024

Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India

Vericiguat works on a pathway not currently targeted by existing heart failure treatments


LANXESS showcases extensive portfolio for the cosmetics industry at in-cosmetics Global
News | April 07, 2024

LANXESS showcases extensive portfolio for the cosmetics industry at in-cosmetics Global

Highly effective preservation solutions ensuring the safety and protection of personal care products


Aster DM Healthcare concludes separation of India and GCC businesses
Healthcare | April 05, 2024

Aster DM Healthcare concludes separation of India and GCC businesses

The company plans to add 1700 beds by FY27 through the organic route


Dabur India expects mid-single digit revenue growth in Q4
News | April 05, 2024

Dabur India expects mid-single digit revenue growth in Q4

International Business is expected to register double-digit growth in constant currency terms


Aurobindo Pharma commissions 4 plants in Andhra Pradesh including Pen-G and 6-APA facilities
News | April 02, 2024

Aurobindo Pharma commissions 4 plants in Andhra Pradesh including Pen-G and 6-APA facilities

These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.